Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 2/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 11/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18630958 | 0.90 | BCL2L1 (0.47) | BCL2BCL2L1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL31129949 | 0.81 | ALDH1A1 (0.51) | MAPTKMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL18630915 | 0.80 | MAPT (0.50) | BCL2BCL2L1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL18642009 | 0.79 | KMT2A (0.49) | BCL2BCL2L1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL18642011 | 0.79 | KMT2A (0.49) | BCL2BCL2L1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL31347224 | 0.78 | MAPT (0.50) | BCL2BCL2L1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL3311487 | 0.77 | LMNA (0.50) | MAPTKMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL18631299 | 0.77 | PTGER4 (0.37) | BCL2BCL2L1MAPTALDH1A1LMNA | |
| SCHEMBL29246422 | 0.76 | ALDH1A1 (0.46) | MAPTSMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL18630658 | 0.75 | MAPT (0.60) | MAPTKMT2ASMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10059701-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-08-28 | — | — | US | disclosed |
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| EP-3350177-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017049068-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BCL2 2167/4885BCL2L1 1372/4885MAPT 2476/4885 |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | BCL2 2167/4885BCL2L1 1372/4885MAPT 2476/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | BCL2 2167/4885BCL2L1 1372/4885MAPT 2476/4885 |
| US-10059701-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | BCL2 2167/4885BCL2L1 1372/4885MAPT 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.